CommercialPrior AuthMedium impact
Preferred Drug Strategy for Medical Benefit Drugs with Therapeutic Equivalents or Alternatives To Be Covered Through Enhanced Prior Authorization
BCBS Oklahoma·OK · Oncology, Rheumatology, Gastroenterology +1 more·Prior Authorization
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Effective Jan 1, 2026, Blue Cross Blue Shield of Oklahoma is implementing enhanced prior authorization for certain medical benefit drugs that have therapeutic equivalents or alternatives. When requesting prior auth for non-preferred drugs, providers will receive a list of preferred therapeutic alternatives that must be considered first.
Action Required
Before January 1, 2026: Billing team must review Medical Benefit Therapeutic Alternatives Summary and referenced medical policies (RX501.051, RX502.061, RX502.030) to identify affected drugs including Infliximab, Pegfilgrastim, Rituximab, and Trastuzumab biosimilars. Update prior authorization workflow to check for preferred therapeutic alternatives before submitting requests. Always verify eligibility through Availity Essentials prior to rendering services to confirm prior authorization requirements.